Evidence map›Paper›PMID 41219883›Full record

ArticleBMC medical imaging2025

Assessing AI-augmented training for multiple sclerosis classification in a basal ganglia radiomics model.

Erick Eduardo López-Ríos, Francisco J Alvarez-Padilla

Abstract read
In one paragraph

Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Erick Eduardo López-RíosTranslational Bioengineering, University of Guadalajara, 1421 Blvd. Marcelino García Barragán, Guadalajara, 44430, México.ORCID 0000-0003-0285-0183
Francisco J Alvarez-PadillaTranslational Bioengineering, University of Guadalajara, 1421 Blvd. Marcelino García Barragán, Guadalajara, 44430, México. francisco.alvarez@academicos.udg.mx.ORCID 0000-0003-0665-5895

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) radiomics is hindered by multicenter variability and limited sample sizes. We evaluated whether GAN-based augmentation (GBA) improves MS classification versus traditional data augmentation (TDA) under center-wise external testing. A conditional GAN generated T1-weighted brain MRIs conditioned on class labels. Ten subcortical regions (including thalamus, putamen, caudate) were segmented with a 3D U-Net; radiomic features (shape, first-order, and texture families) were extracted and selected with LASSO. We used a leave-one-center-out (LOCO) design. All model development, segmentation, cGAN training, feature engineering, and tuning, were performed within the training centers only using inner 5-fold (subject-level 80/20) splits; the entire held-out center was reserved for a single external test. Across centers, GBA yielded small but consistent gains over TDA and real-only training, most evident for a tabular ResNet (average F1 up to 0.957), while confidence intervals overlapped for some metrics. SHAP analyses preserved the salience of basal-ganglia features, supporting biological plausibility. Limitations include a single-country cohort and no public external validation, which constrains generalizability. AI-augmented training provides incremental improvements for MS radiomics under site-held-out testing and motivates broader, international validation and clinically oriented utility analyses.

Indexed as

Basal GangliaMagnetic Resonance ImagingMultiple SclerosisArtificial IntelligenceGenerative Adversarial NetworksGenerative Artificial IntelligenceHumansRadiomicsComputer-aided diagnosisFeature engineeringGenerative AIMultiple sclerosis

Identifiers

PMID41219883
PMCPMC12607199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.